Add Roche to the list of companies expecting to benefit from U.S. tax law changes. The Swiss drug giant expects sales growth to slow this year as the biosimilars threat to its revenue gets real. But a lower tax rate means profits will grow just the same.Original Article
Despite slowing growth, Roche profits are on the move—thanks to tax reform
